Gastroparesis Treatment Market
The Global Gastroparesis Treatment Market, by Drug (Domperidone, Metoclopramide, and Erythromycin); by Type (Post-surgical gastroparesis, Diabetic gastroparesis, and Idiopathic gastroparesis); by Route of Administration (Oral, Intravenous, and Nasal); by Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies); and by Region (Africa, North America, Latin America, Europe, Middle East, and Asia Pacific) from 2022 to 2030.
The market is anticipated to increase as a result of rising measures taken by regulatory agencies and researchers to promote clinical studies and the creation of innovative treatments. Additionally, an increase in the frequency of operations that result in postoperative gastroparesis is predicted to fuel market expansion. Statistics released by the American Society of Metabolic and Bariatric Surgery in 2021, the expected number of bariatric procedures conducted in the U.S. from 2011 to 2019 was around 158,000 surgeries in 2011 and climbed to 256,000 surgeries in 2019.
Click Here for Free Sample Copy (Use corporate email ID Get Higher Priority) @ https://www.coherentmarketinsights.com/insight/request-sample/5123
Impact
The most recent epidemic was the coronavirus (COVID-19) pandemic, which was first identified on December 31, 2019, in Wuhan, China. On March 11, 2020, the World Health Organization classified COVID-19 as a pandemic. The pandemic interfered with the way clinical studies were carried out. This may cause a delay in product approvals, which would prevent the market from expanding. Additionally, the COVID-19 epidemic has had an influence on the economy by directly impacting supply and demand, disrupting distribution routes, and having an economic impact on businesses and financial markets.
Forecast to 2030, by Drug (Domperidone, Metoclopramide, and Erythromycin); Type (Post-Surgical gastroparesis, Diabetic gastroparesis, and Idiopathic gastroparesis); Route of Administration (Oral, Intravenous, and Nasal); Distribution Channel (Africa, North America, Latin America, Europe, Middle East, and Asia Pacific)
Furthermore, a significant emphasis on R&D by leading industry competitors is projected to fuel market expansion. For instance, CinDome Pharma, Inc., a biopharmaceutical firm, stated in September 2019 that the first patient had been recruited in a Phase 2 clinical study of CIN-102. Gastroparesis is being treated using the medication CIN-102. Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical business, declared in October 2021 that the U.S. has given the company approval. Patients with mild to moderate gastroparesis will be enrolled in a Phase 2a clinical investigation of PCS12852 by the Food and Drug Administration (FDA).
For More Information or Query or Customization before Buying, Visit at – https://www.coherentmarketinsights.com/insight/talk-to-analyst/5123
Key Takeaways
A CAGR of 3.6% is anticipated for the worldwide gastroparesis therapy market over the forecast period. Extensive research into therapeutic solutions for gastroparesis is now being conducted due to the poor effectiveness of available treatments and their significant side effects. Three intriguing investigational pharmaceuticals include relamorelin, prucalopride, and aprepitant. The global market for treating gastroparesis will expand as a result of these improvements in treatment options.
Over the course of the forecast period, the metoclopramide category is anticipated to see the quickest CAGR growth in the worldwide gastroparesis treatment market. The drug metoclopramide has promising therapeutic benefits, which are projected to increase demand and propel market expansion.
Diabetic gastroparesis is the category with the greatest CAGR growth from 2022 to 2030. The category is expected to rise due to an increase in the incidence of diabetes. For instance, the International Diabetes Federation estimates that 537 million persons worldwide would have diabetes by 2021.
In terms of mode of administration, the nasal category is expected to develop at the quickest CAGR. The market expansion is projected to be fueled by the approval of technologically sophisticated goods delivered via the nasal route. For instance, the U.S. Food and Drug Administration (FDA) approved GIMOTI nasal spray in 2020 as the first and only nasally given medicine recommended for the treatment of symptoms in individuals with acute and recurring diabetic gastroparesis.
In the worldwide gastroparesis treatment market, the retail pharmacies segment is anticipated to develop at the quickest CAGR over the projected period. Due to both customer preferences for retail pharmacies and the growing number of retail or independent pharmacies throughout the world, the retail pharmacies category is anticipated to have a sizable market share in 2022. For instance, independent pharmacies rose from 22,737 in 2007 to 23,596 in 2015, a gain of 3.8%, according to research published in the PLOS Journal in August 2017.
Over the course of the forecast period, the gastroparesis treatment market is expected to develop most rapidly in Asia Pacific. The major industry players have not yet entered the Asia Pacific market; by raising knowledge of available treatment alternatives, they may benefit from this untapped market.
Salix Pharmaceuticals, Processa Pharmaceuticals, Inc., Atlantic Healthcare, EVOKE PHARMA, Teva Pharmaceutical Industries Ltd., Neurogastrx, Inc., Pfizer, Inc., Vanda Pharmaceuticals, Inc., PTC Therapeutics, ANI Pharmaceuticals, Inc., CinDome Pharma, Inc., Takeda Pharmaceutical Company Limited, Otsuka Holdings Co., Ltd., and GlaxoSmithKline plc, are major market participants in the gastroparesis treatment market.
Avail Discount on various license types on Immediate Purchase @ https://www.coherentmarketinsights.com/insight/buy-now/5123
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Gastroparesis Treatment, By Drug
- Market Gastroparesis Treatment, By Type
- Market Gastroparesis Treatment, By Route of Administration
- Market Gastroparesis Treatment, By Distribution Channel
- Market Gastroparesis Treatment, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- PEST Analysis
- Regulatory Scenario
- Pipeline Analysis
- New Approach for Gastroparesis Treatment
- Treatment Guidelines
- New Product Launches
- Key Development
- Covid 19- Impact Analysis
- Market Value Size and Forecast (2017-2028)
- Global Gastroparesis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply and Demand Analysis
- Key Developments
- Global Gastroparesis Treatment Market, By Drug, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Metoclopramide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Erythromycin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Domperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- Global Gastroparesis Treatment Market, By Type, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Diabetic gastroparesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Idiopathic gastroparesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Post-surgical gastroparesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- Global Gastroparesis Treatment Market, By Route of Administration, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/gastroparesis-treatment-market-4408
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837